The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | The current challenges facing high-risk MDS treatment
Lionel Ades, MD, PhD, Avicenne Hospital, Bobigny, France, outlines the current challenges facing high-risk myelodysplastic syndromes (MDS) treatment. Specifically discussed is improving the results of hypomethylating agents such as azacitidine with other agents and the subsequent issue of side effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
